pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB
S.L
S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis Wi
SAN DIEGO, CA, EU HQ
Public company Type
CNTB · NYSE Ticker
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, EU
- Programs
- 15
- Drugs
- 11
- Patents
- 179
Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
Phase 1 · small molecule · STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
Glycerol Phenylbutyrate 1100 MG/ML [Ravicti] for STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder is a Phase 1 program (small_molecule) at S.L with 1 ClinicalTrials.gov record(s).
Internal code 19-10020997
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- S.L
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
- Status
- active
- Trials
- 1